Abstract
The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [99mTc(CO)3(H2O)3]+ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. 99mTc(CO3)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of 99mTc(CO3)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.
Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor
Current Radiopharmaceuticals
Title: Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Volume: 5 Issue: 1
Author(s): Maria Fernanda Garcia, Ximena Camacho, Victoria Calzada, Marcelo Fernandez, Williams Porcal, Omar Alonso, Juan Pablo Gambini and Pablo Cabral
Affiliation:
Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor
Abstract: The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [99mTc(CO)3(H2O)3]+ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. 99mTc(CO3)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of 99mTc(CO3)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.
Export Options
About this article
Cite this article as:
Fernanda Garcia Maria, Camacho Ximena, Calzada Victoria, Fernandez Marcelo, Porcal Williams, Alonso Omar, Pablo Gambini Juan and Cabral Pablo, Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies, Current Radiopharmaceuticals 2012; 5 (1) . https://dx.doi.org/10.2174/1874471011205010059
DOI https://dx.doi.org/10.2174/1874471011205010059 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Smart Synthetic Polymer Nanocarriers for Controlled and Site-Specific Drug Delivery
Current Topics in Medicinal Chemistry Recent Advances in Experimental Molecular Therapeutics for Malignant Gliomas
Current Medicinal Chemistry - Anti-Cancer Agents Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Mechanism of Action of Volatile Anesthetics: Involvement of Intracellular Calcium Signaling
Current Drug Targets - CNS & Neurological Disorders Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Recent Advances of Aminopyrimidines in Multicomponent Reactions
Current Organic Chemistry Immune System Modulates the Function of Adult Neural Stem Cells
Current Immunology Reviews (Discontinued) Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry
Current Medicinal Chemistry Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design The Urokinase Receptor Interactome
Current Pharmaceutical Design